← back to search

Wen Li

Army Medical University · CN
Area of research
Radiology, Nuclear Medicine and Imaging · Cancer Research · breast cancer drug design
Research interest
Research interests include Breast Cancer Treatment Studies, MRI in cancer diagnosis, Radiomics and Machine Learning in Medical Imaging, and Cancer Genomics and Diagnostics.
h-index
16
citations
898
works
88
NIH funding
primary concept
Medicine
email

Recent publications

Image Quality Assessment of Diffusion-Weighted Imaging (DWI) and Its Impact on Apparent Diffusion Coefficient (ADC) as a Quantitative Imaging Biomarker for Predicting Response to Neoadjuvant Chemotherapy in High-Risk Early Breast Cancer.
Tomography (Ann Arbor, Mich.) 2026cited by 0position: contributordoi
Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
Nature Medicine 2024cited by 38position: middledoi
Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
Nature Medicine 2024cited by 9position: middledoi
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy
Cancer Cell 2023cited by 162position: middledoi
Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy
Cancers 2022cited by 22position: firstdoi
Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk
npj Breast Cancer 2021cited by 52position: middledoi
Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response
Radiology 2021cited by 36position: middledoi
Response-guided treatment optimization in the I-SPY2 trial.
Journal of Clinical Oncology 2021cited by 7position: middledoi
Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL
npj Breast Cancer 2020cited by 81position: firstdoi
Test–retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial
Journal of Magnetic Resonance Imaging 2018cited by 108position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Jessica Gibbs · University of Georgia4 papers (2018–2022)Laura J. Esserman · UCSF Helen Diller Family Comprehensive Cancer Center4 papers (2018–2022)David C. Newitt · University of California, San Francisco3 papers (2018–2022)Nola M. Hylton · UCSF Helen Diller Family Comprehensive Cancer Center3 papers (2018–2021)Savannah C. Partridge · University of Washington2 papers (2018–2022)Bonnie N. Joe · University of California, San Francisco2 papers (2018–2022)Amy L. Delson · University of California, San Francisco2 papers (2021–2021)Mark Jesus M. Magbanua · UCSF Helen Diller Family Comprehensive Cancer Center2 papers (2021–2022)Zheng Zhang · Ministry of Industry and Information Technology1 papers (2018–2018)Debu Tripathy · The University of Texas MD Anderson Cancer Center1 papers (2021–2021)Mark Rosen · Amgen (United States)1 papers (2018–2018)Sheye O. Aliu · University of California, San Francisco1 papers (2018–2018)Rita Nanda · Sun Pharma (India)1 papers (2022–2022)Angela DeMichele · Brigham and Women's Hospital1 papers (2021–2021)Denise M. Wolf · UCSF Helen Diller Family Comprehensive Cancer Center1 papers (2021–2021)Lisa Cimino · University of San Francisco1 papers (2018–2018)Laura van ‘t Veer · UCSF Helen Diller Family Comprehensive Cancer Center1 papers (2021–2021)Barbara LeStage · Dana-Farber Cancer Institute1 papers (2022–2022)Thomas L. Chenevert · University of Michigan–Ann Arbor1 papers (2018–2018)Lamorna Brown Swigart · UCSF Helen Diller Family Comprehensive Cancer Center1 papers (2021–2021)